The aPKC [atypical PKC (protein kinase C)] isoforms ι and ζ play crucial roles in the formation and maintenance of cell polarity and represent attractive anti-oncogenic drug targets in Ras-dependent tumours. To date, few isoform-specific chemical biology tools are available to inhibit aPKC catalytic activity. In the present paper, we describe the identification and functional characterization of potent and selective thieno [2,3-d]pyrimidine-based chemical inhibitors of aPKCs. A crystal structure of human PKCι kinase domain bound to a representative compound, CRT0066854, reveals the basis for potent and selective chemical inhibition. Furthermore, CRT0066854 displaces a crucial Asn-Phe-Asp motif that is part of the adenosine-binding pocket and engages an acidic patch used by arginine-rich PKC substrates. We show that CRT0066854 inhibits the LLGL2 (lethal giant larvae 2) phosphorylation in cell lines and exhibits phenotypic effects in a range of cell-based assays. We conclude that this compound can be used as a chemical tool to modulate aPKC activity in vitro and in vivo and may guide the search for further aPKC-selective inhibitors.
INTRODUCTION
PKC (protein kinase C) isoenzymes are an important family of serine/threonine protein kinases that contribute to many diverse cellular and tissue functions, as well as human disease pathologies including cancer development and progression [1, 2] . The molecular architecture of PKC family members is conserved throughout the cPKC (classical PKC; cPKCα, cPKCβ and cPKCγ ), nPKC (novel PKC; nPKCδ, nPKCε, nPKCη and nPKCθ ) and aPKC (atypical PKC; aPKCζ and aPKCι) isoforms. They all comprise a C-terminal serine/threonine protein kinase domain [belonging to the AGC kinase (protein kinase A/protein kinase G/PKC family kinase) superfamily] and an N-terminal regulatory domain [3] . The kinase domain has a C-terminal extension unique to AGC kinases that contain essential 'priming' phosphorylation sites required for catalytic activation [4] ; in aPKCs, the most C-terminal of these is replaced by a phosphomimetic glutamate residue. The regulatory domain within all PKC isoforms has an inhibitory region (pseudo-substrate motif) and distinctive arrangements of C1, C2 and/or PB1 (Phox/Bem1) domains (the last being exclusive to the aPKCs) that together are crucial for conferring isoform-specific functions [3] .
The aPKC isoforms (PKCζ and PKCι) diverge from other PKC family members as their regulatory domains are unresponsive to diacylglycerol, phosphatidylserine and Ca 2 + . Instead they are regulated by protein interactions, for example with polarity proteins Par-6, Par-3 and the Rho family GTPase cdc42 [5] . These components assemble into an evolutionarily conserved Par-6-aPKC-Par-3 complex present in both invertebrates and vertebrates that controls apical-basal polarity in epithelial cells and anteriorposterior positioning in asymmetric cell division [6, 7] . In addition to an established role in cell polarity, aPKC is required for normal cell proliferation, mitotic spindle orientation [8, 9] and migration [10, 11] .
There has been considerable interest in aPKCs as drug targets due to their role in cancer development and progression [12] . In cancer-specific cell models, PKCζ is required for EGF (epidermal growth factor)-induced migration of human breast and lung cancer cells and CSF-1 (colony-stimulating factor 1) chemotaxis of macrophages and acute monocytic leukaemic cells [13] [14] [15] . PKCι promotes nicotine-induced migration and invasion of lung cancer cells via phosphorylation of m-and μ-calpains [16] and is required for non-adherent cell growth in a Rac-1-dependent manner [17] . The potential importance of aPKC in Her2-driven malignancies was demonstrated when the aberrant polarity induced by forced Her2 dimerization in human mammary epithelial MCF-10A cells embedded in Matrigel TM was partially reversed following genetic disruption of aPKC binding to Par-6 [18] . In model organisms, aPKC has been shown to co-operate with bona fide oncogenes, including Ras and Notch in Drosophila melanogaster, to lead to invasive and metastatic tumours [19, 20] . Furthermore, in transgenic mice K-Ras-induced lung cancer is reduced following depletion of PKCι or its adaptor protein p62 [21, 22] .
In human malignancy, one of the most frequent amplicons is 3q26, the location of the PKCι gene (HGNC symbol PRKCI). PKCι gene amplification leads to high protein levels and is correlated with poor clinical outcomes in squamous cell carcinomas of the lung [17] and oesophagus [23] . High PKCι expression has been correlated with poor prognosis and/or worse stage in an increasing number of human cancers including breast [24] , pancreas [25] , stomach [26] , bile duct [27] and brain [28] . In addition to the compelling evidence for a role of PKCι in human malignancy, the interest in PKCι as a therapeutic target was further enhanced by the finding that elevated PKCι protein is associated with chemotherapy resistance [29] and that depletion/inhibition of PKCι is synergistic with some conventional chemotherapies [30] [31] [32] .
Like many protein kinases, aPKC isoenzymes are amenable to small-molecule chemical inhibition either through their ATPbinding clefts or allosteric pockets [33] . However, there are few selective chemical biology tools to inhibit aPKC catalytic activity. Available tools include the non-selective and relatively impotent BIM-1 (bisindolylmaleimide 1), Gö6983 and Gö6976 compounds or a PKCζ pseudo-substrate peptide containing a membrane-targeting myristoylation site [34] . The development of effective ATP-competitive inhibitors against aPKCs, similar to other protein kinases, has been complicated by challenges in both potency and selectivity [33] . In general, such inhibitors acquire selectivity by associating with both the ATP-binding site and with adjacent residues, which are less well conserved. Other approaches include screening for allosteric inhibitors of PKCζ that target the PIF pocket [35] or blocking PKCι interaction with Par-6, for example with ATM (aurothiomalate), a quite different class of PKCι inhibitor which exhibits potent antitumour activity in lung cancer [36] .
In the present study, we report the identification of an aPKC inhibitor CRT0066854 which is able to mimic both ATP and a key side chain that forms part of the aPKC nucleotidebinding cleft. We define the compound's mechanism of action by crystallographic and biochemical methods and demonstrate its utility through the use of phenotypic cell-based assays. Together, our data indicate that CRT0066854 is a potent and selective chemical tool to modulate aPKC activity both in vitro and in cells.
EXPERIMENTAL

Chemical synthesis of CRT0066854 and CRT0066390
Synthesis of (S)-N*1*-(2-pyridin-4-yl-5,6,7,8-tetrahydrobenzo [4, 5] thieno [2,3- 
Synthesis of 2-pyridin-4-yl-5,6,7,8-tetrahydro-benzo [4, 5] thieno [2,3- 
d]pyrimidin-4-ol (A-1)
To a solution of 4-cyanopyridine (1.25 g, 12 mmol) in dry dioxane (10 ml) was added 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylic acid ethyl ester (2.25 g, 10 mmol) followed by potassium-tert-pentylate 1.7 M in toluene (12 ml, 20 mmol 2-pyridin-4-yl-5,6,7,8-tetrahydro-benzo [4, 5] thieno [2,3- 
Synthesis of 2,4,6-tri-isopropyl-benzenesulfonic acid
d]pyrimidin-4-yl ester (A-2)
To a solution of 2-pyridin-4-yl-5,6,7,8-tetrahydro-benzo [4, 5] thieno [2,3-d] pyrimidin-4-ol (1 g, 3.5 mmol) (A-1) in DCM (dichloromethane, 10 ml) was added 2,4,6-triisopropylbenzenesulfonyl chloride (1.3 g, 4.2 mmol), triethylamine (Et 3 N) (1.5 ml, 10.5 mmol) and DMAP (4-dimethylaminopyridine) (6 mg, 0.05 mmol). The mixture was stirred at room temperature for 1 h. After completion the mixture was diluted with water and the product was extracted into DCM (2×2 ml). The combined extracts were dried with magnesium sulfate, filtered and evaporated under reduced pressure to yield the title compound as a brown solid, which was used without further purification in the next step. LC-MS method: RT: 6.23 min, MI: 550 [M + 1].
Synthesis of (S)-3-phenyl-propane-1,2-diamine (A-3)
To a suspension of (S)-2-amino-3-phenyl-propionamide hydrochloride (540 mg, 2.7 mmol) in DCM (5 ml) was added triethylamine (Et 3 N) (380 μl, 2.7 mmol). The suspension was stirred for 2 h at room temperature, the resulting solid was filtered and the filtrate was concentrated under reduced pressure to yield a white solid, to which was added dropwise a 1 M solution of BH 3 in THF (tetrahydrofuran, 20 ml, 20 mmol), the solution was stirred overnight at reflux. After cooling the solution was hydrolysed by slow addition of an excess of 10 % acetic acid/methanol (30 ml) and refluxed for a further 2 h. The solvent was removed under reduced pressure, and the residue was dissolved in methanol and passed through a SCX-2 cartridge and washed with methanol. The product was released from the cartridge using a solution of 2 M ammonia/methanol. The solvent was evaporated to provide the title compound as a white solid which was used in the next step without further purification. LC-MS method: RT: 0. 36 Synthesis of (S)-N*1*- (2-pyridin-4-yl-5,6,7,8-tetrahydro-benzo [4, 5] thieno [2,3- 
To a solution of 2,4,6-tri-isopropyl-benzenesulfonic acid 2-pyridin-4-yl-5,6,7,8-tetrahydro-benzo [4, 5] thieno [2,3-d] pyrimidin-4-yl ester (A-2) (100 mg, 0.180 mmol) in DMA (dimethylacetamide, 2 ml) was added (S)-3-phenyl-propane-1,2-diamine (A-3) (30 mg, 0.180 mmol) followed by triethylamine (Et 3 N) (50 μl, 0.36 mmol), the mixture was stirred at room temperature for 2 h. After completion the mixture was loaded on to a SCX-2 cartridge and washed with methanol. The product was released from the cartridge using a solution of 2 M ammonia/methanol. The ammonia/methanol eluent was concentrated under reduced pressure and the crude product was purified by preparative HPLC to yield the title compound. [4, 5] thieno [2,3- The tricyclic thienopyrimidine compound ASN2993118 (2-pyridin-4-yl-5,6,7,8-tetrahydro-benzo [4, 5] thieno [2,3-d] pyrimidin-4-ylamine) was purchased directly from Asinex.
Plasmids
For mammalian studies, human PKCι cDNA (GenBank ® accession number NM_002740.5), a gift from T. Biden (Garvan Institute of Medical Research, Australia), was subcloned into pEGFP-C1 vector (Clontech) using 5 -SalI and 3 -BamHI restriction sites. The cDNA contains two start codons at bp 1-3 and bp 28-30 with the second methionine residue denoted as the first amino acid of the protein. LLGL2 (lethal giant larvae 2) cDNA (GenBank ® accession number NM_004524.2), a gift from T. Pawson (Samuel Lunenfeld Research Institute, ON, Canada), was subcloned into pEGFP-C1 with and without a 5 FLAG-tag sequence using 5 -BamH1 and 3 -Sal1 restriction sites. For biochemical and structural studies, the kinase domain of PKCι (residues 239-587) was inserted into a pBacPAK-His3 vector (Clontech) using BamHI and XhoI restriction sites. The vector was modified to have a GST (glutathione transferase) followed by a 3C protease cleavage site upstream of the kinase domain. A C586S mutation was also introduced into the kinase domain using QuikChange ® (Stratagene) according to the manufacturer's instructions in order to avoid oxidative cross-linking during crystallization. • C or on ice. Cells were lysed by sonication and spun down at 30 000 g for 30 min. PKCι k or PKCι were purified using glutathione-Sepharose 4B beads (Amersham Biosciences), followed by removal of the GST affinity tag with GST-3C protease (PreScission Protease, Amersham Bioscience) and ion-exchange chromatography (Hi-Trap Q column, GE Healthcare). The protein was dialysed into the final buffer [25 mM Tris (pH 8.0), 150 mM NaCl, 1 mM EDTA and 1 mM DTT] and concentrated before use.
High-throughput screening and selectivity screens
We performed a small molecule HTS (high-throughput screen) against recombinant PKCι k with confirmed hits profiled against recombinant PKCζ k to verify pan-aPKC inhibition. We screened a 56 000 CRT (Cancer Research Technology) chemical library collection at a single concentration of 30 μM [IMAP (immobilized metal ion-affinity fluorescence polarization) format, Molecular Devices]. The 56 000 compounds comprises 46 000 from a diverse collection and 10 000 from a kinase-focused collection (including in-house compounds). The HTS assay used 10 pM PKCι and 100 nM 5FAM (fluorescein-amidite)-ERMRPRKRQGSVRRRV-NH 2 peptide and 30 μM ATP in a buffer consisting of 20 mM Hepes (pH 7.5), 10 mM MgCl 2 , 1 mM DTT and 0.25 mM EGTA. The PKCι k K m for ATP was determined to be 30 μM using this IMAP assay. We used an isoquinoline sulfonamide H-series compound H-9 as the assay standard (IC 50 = 2 μM). All final Z'-factors were greater than 0.5 and most were above 0.6. The H-9 assay standard inhibition at 2 μM gave 46.7 + − 4.8 % inhibition of PKCι k activity. Hits from the HTS screen gave IC 50 values from 0.2 to 30 μM. The initial hit rate was unusually low for a kinase HTS at 0.2 % with no confirmed hits arising from the kinase-focused subset of our library. As the HTS used a truncated form of PKCι, we profiled our hits against the full-length human PKCι. The tricyclic thienopyrimidine ASN2993118 demonstrated activity against both full-length and the kinase domain of PKCι (as well as the kinase domain of PKCζ ). Further validation of PKCι inhibitory activity was undertaken in orthogonal assay formats with ASN2993118, and mechanistically it was shown to have an ATP-competitive mode of inhibition. These studies confirmed ASN2993118 as a bona fide hit, and it was progressed into lead identification. Lead identification involved assaying modifications to the C 4 position of the central pyrimidine ring of ASN2993118. The Millipore KinaseProfiler TM service (Millipore) was used to determine the selectivity of CRT0066854 against a panel of kinases. This service used a radiometric assay and 1 μM singlepoint concentrations of CRT0066854. An ATP concentration of 30 μM (equivalent to the K m of PKCι k ) was used.
In vitro kinetic assays for PKCι and IC 50 determinations
The ADP Quest kit (DiscoveRx) was used to determine the k cat and K m values for fully primed phospho-species of PKCι k , PKCζ k and the nPKC isoform PKCε k as a positive control (Supplementary  Table S1 at http://www.biochemj.org/bj/451/bj4510329add.htm). This assay uses a coupled reaction to convert ADP into a product that has a fluorescence excitation at 530 nm and emission at 590 nm. Two synthetic peptides, a model substrate peptide (ERMRPRKQGSVRRRV) derived from PKCε and human LLGL2 substrate peptide (LKKSLRQSFRRMRR). For the k cat (app) and K m (app) reactions, the ATP concentration ranged from 0 to 200 μM while the synthetic peptide substrates were kept constant at 200 μM to avoid product inhibition. PKC isoenzyme concentrations were 5 nM for all three isoenzymes. The reactions were measured every 2 min for 30 min in a 384-well plate using a Safire 2 plate reader (Tecan). For determination of IC 50 values, reactions were prepared using 20 μM ATP and 20 μM model substrate peptide. Protein concentrations were the same as indicated in the previous paragraph. Serial dilutions of inhibitors with concentrations ranging from 1 nM to 100 μM were added and fluorescence intensity was measured in end point assay mode.
SPR (surface plasmon resonance) measurements for CRT0066854 binding to PKCι k
To conduct SPR measurements to obtain affinity and on and off rates for the inhibitor, we immobilized an anti-GST antibody (GEHC GST-capture kit) by amine coupling using standard protocols in flow cells 1 and 2. We then captured GST-tagged PKCι k in flow cell 2 using 25 μg/ml in running buffer, 180 s, 5 μl/min. The running buffer consisted of 50 mM Tris, 150 mM NaCl, 10 mM MgCl 2 , 1 mM MnCl 2 , 1 mM DTT and 0.05 % P20 at pH 7.5. A GST control was captured in flow cell 1 using 25 μg/ml in the same running buffer (180 s, 5 μl/min). Then we ran a concentration series of inhibitor CRT0066854 over the captured PKCι k . Concentrations used were 0, 16.125, 32.25, 62.5, 125, 250, 500, 1000, 1500 and 2000 nM.
Crystallography and structure determination
Crystals of PKCι k bound to CRT0066854 were obtained at 20
• C using 200 nl drops formed by 100 nl of protein solution in 20 mM Tris (pH 7.5), 150 mM NaCl and 2 mM DTT buffer (containing a 5-fold molar excess of CRT0066854), mixed with 100 nl of precipitant solution containing 0.2 M ammonium iodide and 20 % (v/v) PEG3350 [poly(ethylene glycol) 3350]. Crystals were cryoprotected using 20 % ethylene glycol. Diffraction data were collected at Diamond [beamline IO3, at a wavelength of 0.92 Å (1 Å = 0.1 nm)] and processed with the CCP4 (collaborative computational project 4) software [37] . Molecular replacement was performed using the program Phaser [38] , using the protein structure of PKC ιk bound to BIM-1 (PDB code 1ZRZ) as a search model. Refinement was carried out with Phenix [39] , using torsion angle NCS (non-crystallographic symmetry) and TLS (translation libration screw-motion; with three TLS groups per protein chain) parameters. For a summary of the crystallographic data, see Table 3 . There are three molecules within the asymmetric unit, denoted A, B and C, with RMSDs (root mean square deviations) between Cα atoms A-B 0.13 Å for 321 pairs, A-C 0.13 Å for 312 pairs and B-C 0.19 Å for 314 pairs. Missing regions in the final model due to poor or non-existent electron density included residues 448-455 and 543-551. These residues belong to an aPKC-specific insert motif (residues 448-455) and the Ade (adenosine-binding) motif respectively. Selected welldefined water molecules were included together with two iodide ions. The position of the iodide ions was confirmed by inspection of an anomalous difference Fourier electron density map. [10] . The cells were cultivated in DMEM and 10 % FBS under 5 % CO 2 conditions.
Antibodies
The following antibodies were used for immunoblotting: mouse monoclonal anti-PKCλ/ι antibody used at a 1:500 dilution (BD Biosciences), mouse monoclonal anti-α-tubulin antibody at a 1:10 000 dilution (Sigma), rabbit polyclonal anti-pLLGL1/2 antibody at a 1:500 dilution (Abnova), rabbit polyclonal anti-phospho-serine PKC substrate antibody used at a 1:500 dilution (Cell Signaling Technology; broad phospho-serine motif recognition for AGC kinase substrates) and rabbit polyclonal anti-GFP (green fluorescent protein) antibody used at a 1:1000 dilution (Santa Cruz Biotechnology). In ELISA, the antipLLGL1/2 antibody (Abnova) was used at a 1:1000 dilution and HRP (horseradish peroxidase)-conjugated goat anti-(rabbit IgG) antibody (Perbio Science) was used at a 1:2000 dilution.
Western blotting
For immunoblotting, lysates or immunoprecipitates were resolved using precast NuPAGE 4-12 % Bis-Tris gels (Invitrogen) and transferred on to nitrocellulose membranes (PROTRAN, Whatman). Immunoblots were blocked in 3 % BSA-TBST (Tris-buffered saline containing 0.1 % Tween 20) and probed with primary antibodies as indicated. Following incubation with species-specific HRP-conjugated secondary antibodies, bands were visualized radiographically. DTT, 10 mM sodium fluoride, complete EDTA-free protease inhibitor cocktail (Roche) and phosphatase inhibitor cocktails (set II + IV; Calbiochem)]. After centrifugation (13 000 g, 4
• C, 10 min), soluble proteins were precleared then incubated with anti-GFP magnetic beads (GFP-TRAP; Chromotek) for 90 min at 4
• C. Beads were washed five times with lysis buffer (containing 260 mM NaCl), then the bound proteins were eluted in Laemmli sample buffer, resolved by SDS/PAGE and analysed by immunoblotting. Where indicated, cells were treated for 2 h before lysis with DMSO (as a control), 10 μM BIM-1 (Calbiochem) or 5 μM Gö6983 (Calbiochem) or CRT0066854.
Transfection
Transient reverse transfections of cDNA for HEK-293 cells were performed on poly-L-lysine precoated plates using Lipofectamine TM 2000 as per the manufacturer's instructions (Invitrogen). Co-transfections of PKCι and LLGL2 were at a 4:1 DNA ratio. HCT-116 cells were transfected 24 h after plating using FuGENE ® HD as per the manufacturer's instructions (Roche). The cells were then grown in normal medium for 36 h before further manipulations. In ELISA, HEK-293 cells were transfected with cDNA using JetPEI reagent as per the manufacturer's instructions (Autogen Bioclear).
ELISA
HEK-293 cells were transfected in a 10-cm dish as per the manufacturer's instructions (Corning). After 16 h, the cells were trypsinized and seeded into a 96-well plate at 1.5×10 4 cells/well and medium was replenished. After a further 24 h, the medium was replaced by new medium and a range of CRT0066854 inhibitor concentrations. After 1 h of inhibitor treatment, lysates were prepared using ice-cold Tris lysis buffer [150 mM NaCl, 20 mM Tris (pH 7.5), 1 mM EGTA, 1 mM EDTA and 1 % Triton X-100]. Lysates were transferred on to an anti-FLAG-coated ELISA plate (Sigma) and incubated for 2 h with gentle shaking, followed by an automated wash step (Tecan plate washer) with wash buffer [50 mM Tris (pH 7.5), 0.15 M NaCl and 0.02 % Tween 20]. The immunocomplexed protein was incubated with anti-pLLGL1/2 primary antibody overnight at 4
• C, followed by an automated wash and then addition of HRP-conjugated secondary antibody. After a further wash, 3,3 ,5,5 -tetramethylbenzidine (Sigma) was added according to the manufacturer's instructions and attenuance was read at 450 nm using an Ascent plate reader (Thermo Labsystems).
Cell viability
CellTitre-Glo ® (Promega) cell viability assay was carried out as per the manufacturer's instructions. The luminescent measurement of ATP was performed using the EnVision plate reader (PerkinElmer).
Soft agar assay
Single-cell suspension of HeLa cells were resuspended in 0.35 % agarose in RPMI 1640 medium and 10 % FBS at a density of 1500 cells/ml. The agarose-cell mixture (3 ml) was added to each 35-mm well that had been precoated with 1.5 ml of 0.5 % agarose. Plates were incubated at 4
• C for 20 min to allow the agarose to set before being placed in the 37
• C incubator for 10-14 days. Colonies were stained with 0.005 % Crystal Violet for 1 h, after which images were taken using a CCD (charge-coupled-device) camera and colony number was counted using ImageJ software version 1.40g.
3D (three-dimensional) cystogenesis assay
The 3D culture of MDCK cells in Matrigel TM was performed as follows: MDCK cells in exponential-phase growth were trypsinized and resuspended in standard medium, supplemented with 2 % low growth factor Matrigel TM (BD Biosciences) at 2×10 4 cells/ml. Each well of an eight-well chamber slide (BD Biosciences) was precoated with 30 μl of 100 % Matrigel TM to which 400 μl of the cell suspension was added. Inhibitors were added on day 1 and the medium of 2 % Matrigel TM in the presence or absence of inhibitor was changed on alternate days for 5 days.
Wound migration assay
Wounds were inflicted by scratching the cell surface with a plastic pipette tip. Images were recorded using a Nikon Eclipse Ti inverted videomicroscope and Coolsnap HQ2 camera (Photometrics). All inhibitor treatments were performed with 1 h pre-incubation. The migration speed was monitored by measuring the change in the area surrounding the wound over time, using Metamorph software. Statistical analysis (ANOVA 2 factors) were performed using Prism Software.
Immunofluorescence microscopy
MDCK cells grown in Matrigel
TM on chamber slides were fixed with 2 % formaldehyde in PBS, washed in PBS and then permeablized with 0.5 % Triton X-100 in PBS. Following a further wash, cells were directly stained with Phalloidin Alexa Fluor ® 546 (1:200 dilution; Invitrogen) and Hoechst dyes (1:5000 dilution; Invitrogen). After a quick rinse with PBS, the cultures were mounted with Prolong Gold hard-set mounting medium (Invitrogen).
MDCK cysts that had their F-actin (filamentous actin) stained with Phalloidin Alexa Fluor ® 546 were visualized with a confocal microscope (Zeiss 510) and an apical lumen assessment was carried out. The middle of the cyst in the z-plane was identified and the following criteria were observed to determine whether the cyst had a 'predominantly single lumen': (i) a continuous F-actin-defined lumen; (ii) the luminal actin staining being more intense than the basal (outside) staining; (iii) a uni-dimensional measurement of the lumen being at least one-third of the cyst diameter; and (iv) the uni-dimensional measurement of the lumen being twice the size of any other luminal structure.
Statistical analysis
Enzyme kinetic constants for PKCι k were determined by fitting the data to the Michaelis-Menten equation using the graphics program Prism (GraphPad Prism, version 5.0d, GraphPad Software). Differences between the treatment groups were assessed by ANOVA with a repeated measurement module using Prism statistical software. P values of <0.05 were regarded as significant. Dose-response curves and the calculation of the Geometric Mean IC 50 values were performed in SARview software (IDPS, version 6.2).
RESULTS
Discovery of potent and selective chemical inhibitors of aPKCs
To identify molecules that inhibit PKCι, a 56 000-compound diverse chemical library assembled by the CRT Discovery made it an attractive starting point for optimization. Exploration of the activity landscape around the central pyrimidine ring of ASN2993118 led to the identification of compounds with a diamine side chain at the pyrimidine C 4 position that exhibited increased inhibitory activity. This included CRT0066854 in which the pyrimidine C 4 position was substituted with a S-3-phenylpropane-1,2-diamine moiety ( Figure 1A, lower panel) .
To characterize CRT0066854 further, we used an ADP Quest TM assay (Discoverx) to generate dose-response curves for fully primed phosphospecies of PKCζ k , PKCι k and the nPKC isoform PKCε k as a control. The k cat and K m kinetic constants were determined for PKCζ k , PKCι k and the nPKC isoform PKCε k using the ADP Quest TM assay (Supplementary Table S1 ). CRT0066854 was used at 10 μM. We used the structurally unrelated PKC inhibitors BIM-1 (10 μM) and Gö6983 (5 μM) from commercial sources as positive controls. IC 50 values for CRT0066854 against PKCζ k and PKCι k were 450 nM and 86 nM respectively ( Figure 1B ). Comparing the IC 50 values measured for BIM-1 (PKCζ k IC 50 = 9.1 μM and PKCι k IC 50 = 5.5 μM), indicates that CRT0066854 is approximately 20-fold more potent for PKCζ k and over 60-fold more potent for PKCι k than BIM-1. A similar increase in potency is observed for CRT0066854 compared with Gö6983 (PKCζ k IC 50 = 13.9 μM and PKCι k IC 50 = 10.7 μM) ( Figure 1B) . Inhibition of the nPKCε k by CRT0066854 is significantly weaker, with a 16-fold higher IC 50 (IC 50 = 7.21 μM) compared with PKCζ k and more than 80-fold greater than the IC 50 for PKCι k . We then measured IC 50 values for full-length PKCζ and PKCι, which gave 639 nM and 132 nM respectively, comparable with those obtained from isolated aPKC kinase domains. Since CRT0066854 has a chiral centre, we prepared its enantiomer CRT0066390 and measured its IC 50 values against full-length PKCι and PKCζ . This showed only low levels of inhibition of aPKC isoenzymes by CRT0066390 (Table 1) .
To examine the selectivity profile of CRT0066854 in vitro, the compound was tested at Millipore using the KinaseProfiler TM screening service (Millipore) against 106 protein kinases at a 1 μM inhibitor concentration, screened at the K m for ATP (Table 2 ). This is a radiometric assay format used with each kinase. The selectivity score S(80) is the number of kinases inhibited by greater than 80 % at 1 μM compound/total number of kinases tested. For CRT0066854, the S(80) score is close to 0.02, which indicates a good kinase selectivity [40] . Moreover, the compound showed striking selectivity for aPKC over other PKC isoenzymes (Table 2) .
To test whether there was selectivity of the tool compound between the PKC subclasses in cells, GFP-tagged cPKCα, nPKCε and aPKCι proteins were expressed in HCT-116 cells and the cultures were treated with CRT0066854 for 30 or 90 min. As a control we used BIM-1 and Gö6983 to potently inhibit full-length novel and cPKC isoenzymes expressed in this cell line (Supplementary Figure S1 at http://www.biochemj. org/bj/451/bj4510329add.htm).
Immuno-complexes were immune-isolated through the GFP-tag and immunoblotted with an anti-phospho-serine-PKC substrate antibody. In CRT0066854-treated cells, the number of phosphorylated substrate bands apparent was significantly diminished for cells overexpressing PKCι, but not PKCα or PKCε, demonstrating aPKC specificity in cells ( Figure 1C ). Together, these data suggested that CRT0066854 would be a potent and selective chemical tool to modulate aPKC activity both in vitro and in cells.
Kinetics of CRT0066854 inhibitor binding to PKCι k
To characterize the interaction of CRT0066854 in solution with purified recombinant PKCι k protein, we used SPR on a BIACORE T200 to measure the kinetics and affinity of this inhibitor. GSTtagged PKCι k was captured using anti-GST monoclonal antibody immobilized via amine coupling. Sensorgrams were fitted to a 1:1 Langmuir binding model and kinetics constants were obtained and an affinity constant of 340 nM was calculated from k d /k a ( Figure 1D, upper panel) . A binding isotherm was also fitted to a 1:1 steady-state binding model and an affinity of 870 nM was obtained in good agreement with the value derived from the rate constants ( Figure 1D , lower panel).
Structural basis for CRT0066854 selectivity for the PKCι kinase domain
To understand both the selectivity and binding mode of CRT0066854 we determined the crystal structure of CRT0066854 bound to PKCι k ( Table 3) . Crystals of PKCι k bound to CRT0066854 contain three very similar PKCι k molecules in the asymmetric unit that each have a single inhibitor bound within the ATP cleft. The overall PKCι k conformation bears many of the hallmarks of an active AGC kinase conformation (Supplementary Figure S2 at http://www.biochemj.org/bj/451/bj4510329add.htm) except for the lack of bound magnesium and the absence of an ordered Ade motif as discussed below [41] . The CRT0066854 compound makes predominantly hydrophobic interactions within the PKCι nucleotide-binding cleft, as well as five hydrogen bonds, including a water-mediated hydrogen bond (Figures 2A  and 2B ). The fused tricyclic scaffold (cyclohexa [4, 5] thieno [2,3-d] pyrimidine) makes hydrophobic contacts with the PKCι k glycine loop, stabilizing a 'closed' conformation. This tricyclic ring system deviates significantly from planarity and is curved with a puckered cyclohexane ring (Figure 2A ). The thieno-1 nitrogen of the pyrimidine ring makes a crucial hydrogen bond to the Thr 386 side chain. The thieno [2,3-d] pyrimidine ring system also has two important substituents: (i) a pyridine substituent at position 2 and (ii) a (2-amino-3-phenylpropyl)(methyl)amine Table 2 Effect of 1 μM CRT0066854 on the activity of 106 protein kinases A radiometric assay was carried out by the Millipore Kinase Profiling Service (Millipore). The assay determined the selectivity of 1 μM single-point concentrations of CRT0066854 against a panel of 106 protein kinases and 30 μM ATP (K m of PKCι k ). The selectivity score S(80) is the number of kinases inhibited by more than 80 % at 1 μM compound/total number of kinases tested. h, human; m, murine. substituent including a benzyl group, a chiral carbon and a primary amine. The pyridine substituent acts as a kinase domain hingebinding moiety by forming a hydrogen bond to the main-chain amide of Val 326 , approximating to the position of the adenine ring of ATP. The primary amine of the 3-phenyl-propane-1,2-diamino headpiece of CRT0066854 makes a crucial charged interaction with both the backbone carbonyl of Asp 373 and the side chain of Asp 330 . Finally, the benzyl group in the inhibitor headpiece binds a small hydrophobic pocket formed by the kinase domain hinge, usually occupied by Phe 543 from the Ade motif [41] ( Figure 2C ; compare left-hand and middle panel). The benzyl group also makes an orthogonal π-stacking interaction with the pyridine ring hinge-binder, thus locking the inhibitor into a distinctly nonplanar and U-shape conformation (Figure 2A) .
Percentage of activity
Superimpositions of CRT0066854 and ATP-bound structures of PKCι k indicate the general equivalence of the benzyl moiety and Phe 543 ( Figure 2D ). An important consequence of inhibitor binding is that the entire Ade motif, including Phe 543 from the Phe-Xaa-Xaa-Phe motif, becomes disordered, whereas it is an integral part of the ATP-binding cleft in the ATP-PKCι k c The Authors Journal compilation c 2013 Biochemical Society 
CRT0066854 inhibition of LLGL2 phosphorylation in cells
LLGL is a recognized substrate of aPKC in D. melanogaster [43] and in immunocomplexes from HEK-293 cells expressing exogenous aPKC [44] . As LLGL2 is expressed at low levels in HEK-293 cells and due to the lack of a sensitive phosphospecific antibody against LLGL1/2, we used a co-expression system of aPKC and LLGL2 to evaluate the cellular IC 50 of CRT0066854 in HEK-293 cells. Treatment of HEK-293 cells, co-transfected with PKCι wild-type and FLAG-tagged LLGL2, with CRT0066854 (0.125-8 μM) for 1 h led to a reproducible dose-dependent reduction in LLGL2 phosphorylation as seen by Western blotting ( Figure 3A) . In order to test this robustly in a high-throughput format, the phosphorylation signal window was optimized using the co-transfection of constitutively active PKCι-A120E [45] and FLAG-tagged LLGL2 and an ELISA was established. This demonstrated that CRT006854 has a cellular phospho-LLGL2 IC 50 of 0.87 μM comparable with the IC 50 measured in vitro against PKCι ( Figure 3B ).
Effect of CRT0066854 on A549 lung carcinoma cell viability
A549 cells are K-Ras mutant cells of lung origin, known to be dependent on PKCι for survival [17] . The A549 cells were treated with CRT0066854 for 48 h at various concentrations (0.01-20 μM), and cell viability determined by the CellTitre-Glo luminescent assay. An IC 50 of 3.47 μM was obtained from three independent determinations ( Figure 3C ).
Decreased colony formation due to CRT0066854
Although a reduction in adherent cell growth has been reported following the depletion of PKCι in selected cell lines [46] , the anti-proliferative effects appear more pronounced for nonadherent cell growth [17, 46] . As such, we cultured HeLa cells, which reliably form colonies within 12 days when embedded in soft agar, and replenished inhibitor (0.1-10 μM) on alternate days. Two separate inhibitors were used for these experiments, the aPKC-specific CRT0066854 and its enantiomeric equivalent CRT0066390, which is essentially inactive towards PKCι in vitro (Table 1) . At 1 μM the CRT0066854 inhibitor led to a 65 % decrease in colony formation and, as expected, the same dose of CRT0066390 resulted in considerably less suppression of colony formation (25 % decrease) ( Figures 3D and 3E ). This is consistent with CRT0066854 having a specific cellular effect via PKCι inhibition.
Inhibition of polarized epithelial morphogenesis by CRT0066854
Depletion of PKCι in cells using RNAi (RNA interference) leads to impaired luminal morphogenesis in epithelial cell 3D cysts as a consequence of impaired spindle formation and apical-basal polarity [9, 47] . We therefore tested whether chemical inhibition could induce the same phenotype in MDCK cells embedded in Matrigel TM . MDCK cells are widely used as models for studying epithelia, as they have clear apical-basolateral polarity and polarize in 2D (two-dimensional) and 3D cell cultures. In Matrigel TM , MDCK cells are known to form cysts with a single lumen. We determined the number of MDCK cysts that had a PSAL (predominantly single apical lumen) after growing in the presence of 0, 0.33 or 1 μM concentrations of CRT0066854. Surprisingly, inhibitor addition caused significant disruption to lumen formation, resulting in a multiple luminal morphology ( Figure 4A ). This disruption in lumen formation was dosedependent and quantification of this effect indicated that at 1 μM concentrations of CRT0066854 there was a 50 % reduction in PSALs compared with a DMSO control ( Figure 4B ).
CRT0066854 impedes directed migration of NRK cells
Depletion of aPKC using RNAi decreases the rate of healing in an NRK cell scratch-wound assay due to an impairment of the polarized delivery of the exocyst to the cell's leading edge [10] . We used this model to test the effect of aPKC inhibition by CRT0066854 on directional migration. Scratch wounds were generated in wells of confluent NRK cells after which DMSO, or 3, 6 or 12 μM CRT0066854 was added to the wells and time-lapse imaging recorded the wound healing over 10 h (Supplementary Movie S1 at http://www.biochemj.org/ bj/451/bj4510329add.htm). Both 6 μM and 12 μM CRT0066854 led to a significant reduction in wound healing, with 12 μM halving the normalized migration speed (Figures 4C and 4D) . Note that optimum knockdown of aPKCs in this model reduces migration by 60 % [10] . 
DISCUSSION
In the present study, we report the identification and characterization of a selective inhibitor of the aPKC isoenzymes. Selectivity and potency issues have proved particularly challenging in the search for inhibitors of individual PKC isoforms, particularly aPKCζ and aPKCι, where all commercially available inhibitors have greater efficacy for the cPKCs and nPKCs [34] . The discovery of CRT0066854 and a knowledge of the detailed contacts it makes within the aPKC kinase ATPbinding cleft demonstrates that isoform specificity can be obtained using the residues surrounding the nucleotide-binding site, and provides a useful starting point for rational design of even more potent and specific inhibitors. Our crystallographic analysis has revealed that CRT0066854 has a bifunctional inhibitory effect. First, it is a competitive ATP inhibitor, binding within the nucleotide-binding pocket of aPKC. Secondly, it uses a benzyl group to displace the Ade motif from a peripheral hinge pocket adjacent to the nucleotide cleft and prevents it forming a functional ATP-binding pocket. These two features ensure that CRT0066854 is highly selective for aPKC. Some strain/induced fit is evident within the compound in view of its lack of planarity when bound to PKCι k . Inhibitory effects on other kinases such as ROCK2 and PRK2 may be due to the presence of a similar phenyl group equivalent to Phe 543 , suggesting that related scaffolds may permit a more generic approach towards inhibiting AGC kinases bearing an Asn-Phe-Asp motif. Binding isotherms show that the inhibitor has a low off-rate, generally deemed to be an advantageous feature for a kinase inhibitor.
Recent studies have shown differential effects between PKCζ and PKCι for compounds targeting other aPKC-specific pockets outside of the ATP cleft [35, 48] . The selectivity of CRT0066854 shown in the present study for both aPKCζ and aPKCι could prove useful in both clinical and research settings. We provide compelling evidence for both in vitro and phenotypic effects of CRT0066854 using a range of cellular assays relevant to cancer therapy. Non-adherent cell growth, migration and aberrant polarity are all processes exploited by cancer and were more affected by CRT0066854 than adherent cell growth. This differential dependence on aPKC for 3D and 2D cellular phenotypes has been demonstrated previously by genetic depletion of aPKC [17] , and together with the work described in the present paper, supports the role of CRT0066854 as a selective aPKC inhibitor in cells. PKCι overexpression has been linked to several types of cancer, including non-small-cell lung cancer and ovarian cancer [17, 49, 50] and further optimization of inhibitors on the basis of the CRT0066854 structure could yield more specific cancer therapeutics. CRT0066854 and its derivative compounds will be useful tools to further dissect PKCζ and PKCι roles in establishing cell polarity and growth-factor-stimulated signalling pathways.
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